Innovative Research Groupe de recherche uro-onco -

Innovative Research

Welcome the research lab of Dr. Fred Saad

At the forefront of innovation in uro-oncology, Dr. Fred Saad leads a world-renowned research program dedicated to transforming the treatment landscape for genitourinary cancers. As Full Professor and Head of the Department of Urology, as well as Director of Urological Oncology at the University of Montreal Hospital Center (CHUM), Dr. Saad merges clinical excellence with cutting-edge molecular research to develop novel therapeutic strategies and identify prognostic tools. He also serves as Director of the Molecular Oncology Laboratory for Prostate Cancer at the Montreal Cancer Institute, while overseeing oncology research at the CHUM Research Center, where he drives forward multidisciplinary efforts to improve patient outcomes.

Our research team focuses on:

Molecular oncology and the mechanisms driving cancer progression
Development of novel therapeutics for advanced prostate cancer
Identification of prognostic biomarkers to personalize treatment
Collaborative clinical trials that shape global standards of care.

Developing Scientific Initiatives

M24-742

A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer

Study Objective:

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Cras quis lorem vitae quam semper ultricies. Etiam vitae lectus vehicula, condimentum justo vel, semper leo. Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia curae; Morbi in ex quis odio rhoncus tempor. In tincidunt, ligula non sollicitudin consectetur, nunc eros convallis urna, ut malesuada velit sem at lacus. Sed sodales, sem faucibus malesuada euismod, arcu erat pharetra sapien, sit amet convallis ipsum magna vitae nibh. Curabitur et justo sit amet metus ullamcorper dictum vel ut est. Ut in dignissim erat, pellentesque pharetra ante. Quisque lobortis sollicitudin ultricies. Proin in gravida metus, vitae laoreet nulla. Donec vitae turpis eu quam dapibus aliquam ac quis diam. Nunc vel rhoncus velit, at mattis augue. Cras tempor porttitor metus, in luctus tortor aliquet quis.

Implications for Patient Care:

PAnTHA

First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC

Study Objective:

Implications for Patient Care:

The Lorem ipsum dolor sit amet, consectetur adipiscing elit. Cras quis lorem vitae quam semper ultricies. Etiam vitae lectus vehicula, condimentum justo vel, semper leo. Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia curae; Morbi in ex quis odio rhoncus tempor. In tincidunt, ligula non sollicitudin consectetur, nunc eros convallis urna, ut malesuada velit sem at lacus. Sed sodales, sem faucibus malesuada euismod, arcu erat pharetra sapien, sit amet convallis ipsum magna vitae nibh. Curabitur et justo sit amet metus ullamcorper dictum vel ut est. Ut in dignissim erat, pellentesque pharetra ante. Quisque lobortis sollicitudin ultricies. Proin in gravida metus, vitae laoreet nulla. Donec vitae turpis eu quam dapibus aliquam ac quis diam. Nunc vel rhoncus velit, at mattis augue.

INR731 in mCRPC

A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer

Study Objective:

The MEVPRO-1 study investigates the efficacy of mevrometostat (PF-06821497), an oral inhibitor of
EZH2, in combination with enzalutamide, in patients with metastatic castration-resistant prostatecancer (mCRPC) who have progressed following abiraterone acetate treatment. The trial comparesthis combination to either enzalutamide alone or docetaxel chemotherapy, assessing its impact on radiographic progression-free survival.

Implications for Patient Care:

The study explores whether blocking EZH2, a gene involved in turning off other genes, can affect how advanced prostate cancer grows and responds to treatment. By combining an EZH2 inhibitor with hormone-targeting therapy, researchers aim to understand how changes in gene regulation may help control metastatic castration-resistant prostate cancer and guide future treatment strategies.

TulmiSTAR-02

Étude en deux phase: Phase I sur l’escalade de dose du tulmimétostat (DZR123) en combinaison avec le darolutamide ou l’abiratérone, suivie d’une étude de Phase II ouverte, randomisée, d’expansion de dose visant à évaluer l’innocuité et l’efficacité du tulmimétostat en combinaison avec le darolutamide versus le darolutamide seul chez des patients atteints d’un cancer de la prostate métastatique sensible aux hormones.

Study Objective:

Implications for Patient Care:

EvoPAR-Prostate05

Saruparib in Combination With Physician’s Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

Study Objective:

Implications for Patient Care:

ProstACT Global

A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 3 Study of Lutetium (177Lu) Rosopatamab Tetraxetan in Combination With Standard of Care Versus Standard of Care Alone in Patients With PSMA Positive Metastatic Castration-Resistant Prostate Cancer Previously After Androgen Receptor Pathway Inhibitor Treatment

Study Objective:

Implications for Patient Care:

InavoPC

A Study to Test Inavolisib Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Study Objective:

Lorem ipsum dolor sit amet consectetur adipiscing elit mollit quibusdam dolor id proident occaecat voluptatum cumque do blanditiis sunt non blanditiis vel id quos culpa non pariatur facilis nam commodo veniam id est officia blanditiis similique cupidatat dolor id proident in nostrud et deleniti consectetur dolores excepturi at quos commodoeffect.

Implications for Patient Care:

Elorem ipsum dolor sit amet consectetur adipiscing elit mollit quibusdam dolor id proident occaecat voluptatum cumque do blanditiis sunt non blanditiis vel id quos culpa non pariatur facilis nam commodo veniam id est officia blanditiis similique cupidatat dolor id proident in nostrud et deleniti consectetur dolores excepturi at quos commodo interventions.

KLK2 PASenger

Phase 3, randomized, open label study evaluating pasritamig (JNJ 78278343), a T cell–engaging agent targeting human kallikrein 2, in combination with docetaxel versus docetaxel alone in participants with metastatic castration resistant prostate cancer

Study Objective:

Implications for Patient Care:

The XALience Trial

A Study of Xaluritamig Plus Abiraterone Versus Investigator’s Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer.

Study Objective:

Implications for Patient Care:

ABLE-22

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer (ABLE-22)

Study Objective:

Implications for Patient Care:

ABLE-32

A Phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

Study Objective:

Implications for Patient Care:

Legend – EG70

A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients With BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) and High-Risk NMIBC Patients Who Are BCG Naïve or Received Incomplete BCG Treatment

Study Objective:

Implications for Patient Care:

CCTG PR25

A Randomized Phase III Trial Investigating Platinum and Taxane Chemotherapy in Metastatic Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes.